Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08) Article

Wen, Patrick Y, Yung, WK Alfred, Lamborn, Kathleen R et al. (2009). Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08) . NEURO-ONCOLOGY, 11(6), 853-860. 10.1215/15228517-2009-010

Open Access

cited authors

  • Wen, Patrick Y; Yung, WK Alfred; Lamborn, Kathleen R; Norden, Andrew D; Cloughesy, Timothy F; Abrey, Lauren E; Fine, Howard A; Chang, Susan M; Robins, H Ian; Fink, Karen; DeAngelis, Lisa M; Mehta, Minesh; Di Tomaso, Emmanuelle; Drappatz, Jan; Kesari, Santosh; Ligon, Keith L; Aldape, Ken; Jain, Rakesh K; Stiles, Charles D; Egorin, Merrill J; Prados, Michael D

sustainable development goals

authors

publication date

  • December 1, 2009

webpage

published in

keywords

  • AUTOCRINE
  • CELLS
  • CHRONIC MYELOID-LEUKEMIA
  • Clinical Neurology
  • EXPRESSION
  • FACTOR PDGF
  • GROWTH-FACTOR RECEPTORS
  • HYDROXYUREA
  • Life Sciences & Biomedicine
  • MALIGNANT GLIOMAS
  • Neurosciences & Neurology
  • Oncology
  • PHARMACOKINETICS
  • Science & Technology
  • TYROSINE KINASE
  • imatinib
  • meningioma
  • pharmacokinetics
  • toxicities

Digital Object Identifier (DOI)

publisher

  • OXFORD UNIV PRESS INC

start page

  • 853

end page

  • 860

volume

  • 11

issue

  • 6